Search Results

You are looking at 41 - 50 of 282 items for :

  • All content x
Clear All
Free access

Hongbin Liu, Anthony E Dear, Lotte B Knudsen, and Richard W Simpson

protected from the development of biochemical abnormalities associated with endothelial cell dysfunction and development of atherosclerosis ( Eitzman et al . 2000 , Mao et al . 2004 ). Liraglutide, an acylated glucagon-like peptide-1 (GLP-1) analogue, has

Free access

Shin-ya Ueda, Takahiro Yoshikawa, Yoshihiro Katsura, Tatsuya Usui, and Shigeo Fujimoto

number of gastrointestinal hormones, such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1 or GCG as listed in the HUGO Database; Huda et al . 2006 , Näslund & Hellström 2007 , Wren & Bloom 2007 ). PYY is recognized as a satiety factor

Free access

Bo Ahrén, Maria Sörhede Winzell, and Giovanni Pacini

glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP; Vilsboll & Holst 2004 , Drucker 2006 ). The effect is, however, also partially achieved by autonomic nerves activated by oral glucose. Thus, cholinergic nerves

Free access

Benjamin J Lamont and Sofianos Andrikopoulos

Introduction The incretins glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) act via specific G-protein-coupled receptors to potentiate insulin secretion from pancreatic β-cells in a glucose-dependent manner

Free access

Patricia Vázquez, Isabel Roncero, Enrique Blázquez, and Elvira Alvarez

facilitate the action of these proteins involved in the signalling process ( Pawson & Scott 1997 ). The glucagon-like peptide-1 (GLP-1) receptor is a member of the G-protein-coupled receptor subfamily ( Dillon et al. 1993 , Thorens 1993 , Thorens

Free access

Patrice D Cani, Catherine A Daubioul, Brigitte Reusens, Claude Remacle, Grégory Catillon, and Nathalie M Delzenne

( Reimer & McBurney 1996 , Cani et al. 2004 ). In the intestine, the post-translational modification of the proglucagon gene by prohormone convertase 1 (PC1) leads to the production of glucagon-like peptide-1(7–36) amide (GLP-1(7–36) amide) which, among

Free access

Bernard Khoo and Tricia Mei-Mei Tan

regain ( King et al. 2019 ). As a result, there is still an unmet need for other approaches to the treatment of obesity and associated T2D. The gut hormones, led by GLP-1, have emerged over the past few years as a potential answer to this need. This

Free access

Catia Martins, Linda M Morgan, Stephen R Bloom, and M Denise Robertson

), peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and pancreatic polypeptide (PP) ( Blundell 1991 , King et al. 1997 b ). These metabolic and endocrine signals are then received and processed by specific areas in the hypothalamus and brainstem

Free access

Sehee Kim, Minho Moon, and Seungjoon Park

pharmacological intervention of MMP-3 and microglial activation could be considered as plausible candidates for neuroprotective agents in PD. Glucagon-like peptide-1 (GLP-1), an endogenous 30-amino acid gut–brain peptide hormone, is synthesized from proglucagon

Free access

Hong Lan, Galya Vassileva, Aaron Corona, Li Liu, Hana Baker, Andrei Golovko, Susan J Abbondanzo, Weiwen Hu, Shijun Yang, Yun Ning, Robert A Del Vecchio, Frederique Poulet, Maureen Laverty, Eric L Gustafson, Joseph A Hedrick, and Timothy J Kowalski

fall into two major categories: drugs that improve insulin sensitivity, and those that increase insulin secretion from β-cells. Agents that enhance insulin secretion in a glucose-dependent manner, such as glucagon-like peptide-1 (GLP-1) mimetics (e